2型糖尿病：企業と競争環境...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
3 Market Outlook 15
3.1 Global Markets 15
3.1.1 Forecast 15
3.1.2 Drivers and Barriers – Global Issues 21
4 Current and Future Players 23
4.1 Overview 23
4.2 Trends in Corporate Strategy 26
4.3 Company Profiles 27
4.3.1 Eli Lilly 27
4.3.2 Bristol-Myers Squibb 30
4.3.3 Novo Nordisk 33
4.3.4 Sanofi 36
4.3.5 GlaxoSmithKline 39
4.3.6 AstraZeneca 41
4.3.7 Merck & Co 43
4.3.8 Boehringer Ingelheim 45
4.3.9 Takeda 47
4.3.10 Roche 49
4.3.11 Pfizer 51
4.3.12 Johnson & Johnson 53
5 Appendix 55
5.1 Bibliography 55
5.2 Abbreviations 57
5.3 Methodology 60
5.4 Forecasting Methodology 60
5.4.1 Diagnosed Type 2 Patients 60
5.4.2 Percent Drug-Treated Patients 61
5.4.3 Drugs Included in Each Therapeutic Class 61
5.4.4 Launch and Patent Expiry Dates 62
5.4.5 General Pricing Assumptions 63
5.4.6 Individual Drug Assumptions 64
5.4.7 Generic Erosion 73
5.4.8 Pricing of Pipeline Agents 73
5.5 Physicians and Specialists Included in this Study 75
5.6 About the Authors 77
5.6.1 Analyst II – CVMD 77
5.6.2 Therapy Director – CVMD and Infectious Disease 77
5.6.3 Global Head of Healthcare 78
5.7 About GlobalData 79
5.8 Disclaimer 79